financetom
Business
financetom
/
Business
/
Muthoot Finance hikes stake to 59% in microfinance subsidiary for Rs 43 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Muthoot Finance hikes stake to 59% in microfinance subsidiary for Rs 43 crore
Sep 1, 2023 4:03 AM

Gold financing company Muthoot Finance Ltd on Friday said that it has acquired an additional stake of 2.05 percent in its subsidiary Belstar Microfinance Ltd in a cash deal of Rs 43 crore.

Share Market Live

NSE

Following the acquisition, the gold loan provider’s total shareholding in the Tamil Nadu-based microfinance company has increased to 59.02 percent from 56.97 percent earlier, the company stated in an exchange filing.

The equity stake is purchased from promoters through off-market transactions, Muthoot Finance added.

Belstar Microfinance Ltd is a subsidiary of Muthoot Finance Ltd. Some of the directors of Muthoot Finance are directors on the board of Belstar Microfinance.

The microfinance company had a turnover of Rs 1,031.26 crore in 2022-23 as against Rs 727.22 crore in 2021-22 and Rs 551.40 crore in 2020-21.

Muthoot Finance in 2017 had acquired a 53 percent stake in Belstar as part of its diversification strategy. Subsequently, it has increased its stake in the microfinance lender.

Belstar Microfinance is reportedly looking to come out with an IPO at a valuation of Rs 3,000-4,000 crore. The company is a leading MFI in Tamil Nadu. It had a loan book of Rs 6,227 crore in 2022-23.

Muthoot Finance last month had announced additional equity infusion of Rs 400 crore in another wholly-owned subsidiary Muthoot Money Ltd.

Additional equity infusion was aimed at strengthening the capital base and improving the capital adequacy ratio of the company.

Muthoot Finance last month reported a 21.6 percent year-on-year growth in standalone net profit to Rs 975.1 crore in Q1 of FY24 against Rs 802 crore in the year-ago quarter.

The net interest income (NII) of the lender jumped 23.8 percent year-on-year to Rs 1,934.9 crore against Rs 1,562.3 crore in the same period previous fiscal.

Muthoot Finance shares were trading 0.14 percent lower at Rs 1,258.90 apiece on BSE at 12.02 PM.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Tonix Pharmaceuticals (TNXP) Stock Is Falling
Why Tonix Pharmaceuticals (TNXP) Stock Is Falling
Jul 8, 2024
Tonix Pharmaceuticals Holding Corp ( TNXP ) shares are trading lower by 11.3% to $0.71 during Monday’s session after the company announced receipt of the formal minutes from a recent pre-New Drug Application meeting with the FDA for Tonmya for the management of fibromyalgia. What Happened? Tonix Pharmaceuticals ( TNXP ) earlier Monday announced that it received formal minutes from...
TD's chief compliance officer departs amid US anti-money laundering probe
TD's chief compliance officer departs amid US anti-money laundering probe
Jul 8, 2024
TORONTO (Reuters) - TD Bank's chief compliance officer has left the bank, according to a memo sent internally, at a time the Canadian lender faces U.S. regulators and the Justice Department in a probe related to its anti-money laundering program. Monica Kowal, who joined the bank in 2017, left the company this week, and will be replaced by Deputy Chief...
SolarEdge Technologies Inventory, Demand Headwinds to Taper Off in 2025, BofA Says
SolarEdge Technologies Inventory, Demand Headwinds to Taper Off in 2025, BofA Says
Jul 8, 2024
12:24 PM EDT, 07/08/2024 (MT Newswires) -- SolarEdge Technologies' ( SEDG ) current share price slump is factoring in an unlikely worst-case scenario of inventory writedowns and liquidity challenges, BofA Securities said in a note Monday. Residential demand is softening and the European market is still facing substantial inventory headwinds. There is a concern that inventory congestion and reduced sales...
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
Jul 8, 2024
Monday, IDEAYA Biosciences Inc ( IDYA ) released clinical data for the IDE397 Phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients (NSCLC). “IDE397 is a potential first-in-class MAT2A inhibitor, that is being advanced as a monotherapy agent in priority MTAP-deletion solid tumor types and in high conviction rational combinations, including with Amgen’s investigational...
Copyright 2023-2026 - www.financetom.com All Rights Reserved